Hepatobiliary disease after bone marrow transplant: A cross‐sectional study of 377 patients
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.17756 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2024. Written by Maria Gabriela Fernandes Dezan and 8 co-authors. Institution: Instituto D'Or de Pesquisa e Ensino (IDOR) and Hospital São Rafael-Gastro-Hepatology Service, Hospital São Rafael, Salvador, Bahia, Brazil. Major MEDLINE topics: Graft vs Host Disease, Hepatitis. Cited 4 times so far (Crossref); 28 references.
Abstract (original language)
Background
Bone marrow transplantation (BMT) is a standard treatment for several haematologic conditions. Following BMT, patients may develop hepatobiliary complications that impact morbidity and mortality. The differential diagnosis may include drug‐induced liver injury (DILI), sepsis‐associated liver injury (SALI), sinusoidal obstruction syndrome (SOS), graft‐versus‐host disease (GVHD), viral hepatitis, ischaemic hepatitis, and fulminant hepatitis.
Aims
To evaluate the frequency, clinical characteristics, and outcomes of patients with hepatobiliary alterations associated with BMT in a tertiary referral centre.
Methods
This was a cross‐sectional study with data collected from the medical records of patients undergoing BMT between January 2017 and June 2022. We diagnosed hepatobiliary complications based on established criteria.
Results
We included 377 patients; 55.7% had hepatobiliary complications. Female gender, pre‐BMT hepatobiliary alteration, and haploidentical allogeneic transplantation were associated with increased risk with odds ratios (OR) of 1.8 ( p = 0.005), 1.72 ( p = 0.013) and 3.25 ( p = 0.003), respectively. Patients with hepatobiliary complications spent longer in the hospital than those without (27.7 × 19.3 days, respectively; p < 0.001). Among 210 patients with hepatobiliary complications, 28 died compared to 5 of 167 without complications (OR 4.98; p = 0.001).
Conclusions
Hepatobiliary complications are frequent in patients undergoing BMT. There is a greater risk of their occurrence in women, people with pre‐BMT liver alterations, and in haploidentical transplants. The occurrence of these complications increases the length of stay and is associated with a higher risk of death.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Instituto D'Or de Pesquisa e Ensino (IDOR) and Hospital São Rafael-Gastro-Hepatology Service, Hospital São Rafael, Salvador, Bahia, Brazil.
- Gastro-Hepatology Service-University Hospital Professor Edgard Santos (HUPES), Federal University of Bahia, Salvador, Bahia, Brazil.
- Postgraduate Program in Medicine and Health, Federal University of Bahia, Salvador, Bahia, Brazil.
- Instituto D'Or de Pesquisa e Ensino (IDOR) and Hospital São Rafael-Hematology Service, Hospital São Rafael, Salvador, Bahia, Brazil.
- Hematology Service-University Hospital Professor Edgard Santos (HUPES), Federal University of Bahia, Salvador, Bahia, Brazil.
ORCID profiles: Andre Castro Lyra
Cite
APA
Dezan, M. G. F., Cavalcante, L. N., Silva, H. R. C., de Moura Almeida, A., Dos Santos de Assis, L. H., de Freitas, T. T., de Araújo, M. A. S., Cotrim, H. P., & Lyra, A. C. (2024). Hepatobiliary disease after bone marrow transplant: A cross‐sectional study of 377 patients. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17756
Vancouver
Dezan MGF, Cavalcante LN, Silva HRC, de Moura Almeida A, Dos Santos de Assis LH, de Freitas TT, et al. Hepatobiliary disease after bone marrow transplant: A cross‐sectional study of 377 patients. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17756
BibTeX
@article{Dezan2024,
author = {Dezan, Maria Gabriela Fernandes and Cavalcante, Lourianne Nascimento and Silva, Hugo Rodrigues Carvalho and de Moura Almeida, Alessandro and Dos Santos de Assis, Luiz Henrique and de Freitas, Tiago Thalles and de Araújo, Marco Aurélio Salvino and Cotrim, Helma Pinchemel and Lyra, Andre Castro},
title = {Hepatobiliary disease after bone marrow transplant: A cross‐sectional study of 377 patients},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.17756}
}
EUVIMED